| 基于“痰瘀互结”理论探究中医药治疗肺癌新进展 |
| Progress of TCM treatment of lung cancer based on the theory of "interjunction of phlegm and blood stasis" |
| DOI： |
| 中文关键词: 痰瘀互结 中医药 肺癌 药效机制 |
| 英文关键词: Interjunction of phlegm and blood stasis Traditional Chinese medicine Lung cancer Pharmacodynamic mechanism |
| 基金项目:国家自然科学(No. 82204844); 河南省科技攻关项目(No. 222102310468) |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 肺癌一直以来居于死亡率最高的恶性肿瘤之一,是严重威胁人类健康的一类疾病。长期以来,无论现代医学靶向药物的进步,还是免疫药物的创新,对肺癌的控制和转移生长的抑制,仍是医者亟需攻克的难题。基于其疾病的复杂性,中医药长期以来发挥了抗肿瘤的多重优势,临床中以“痰瘀互结”所致证型多见,应用化痰解瘀相关药物治疗后,取得了明显疗效。现就其病因病机归纳、理法方药应用以及药效机制分析进行综述。 |
| 英文摘要: |
| Lung cancer is a serious threat to human health, and is still the highest mortality rate of malignant tumors. Even with the progress of targeted drugs and the emergence of immune drugs, the control of lung cancer and the inhibition of metastatic growth are still difficult problems that doctors need to overcome. Based on the complexity of its diseases, traditional Chinese medicine has played an anti-tumor advantage since ancient times. The syndrome type caused by "phlegm and blood stasis interlocking" is common in clinic. After the application of phlegm-eliminating stasis-related drugs treatment, the effect is remarkable. This article summarized the etiology and pathogenesis, the application of principles, methods and drugs and the analysis of pharmacodynamic mechanism. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|